First published on 11 May 2021
Abstract Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made […]
First published on 04 Mar 2021
Sarcopenia is a progressive and generalised disorder of skeletal muscle strength, function, and mass that is most commonly associated with the normal ageing process although is increasingly recognised in inflammatory bowel disease and liver disease. In this edition, Hollingworth and […]
First published on 24 Jun 2020
In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis. Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for […]
First published on 02 Jun 2020
Guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society Abstract Pregnant women with IBD are at increased risk of adverse pregnancy outcomes. Comprehensive guidelines on medical management have been published; yet, there is […]
First published on 24 Apr 2020
The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order […]
First published on 20 Sep 2019
Corresponding Author Dr Christian Selinger, Leeds Gastroenterology Institute Telephone: +44 113 206 8768 Email: Christian.selinger@web.de This position statement aims to provide guidance for clinicians involved in the care of pregnant patients with IBD. The focus of the position statement is on […]
First published on 29 Jul 2019
This latest briefing provides: Clinical advice when a patient needs to switch from the selected biosimilar to an alternative product Data on the uptake of biosimilars by region (at the end of May 2019) An update on the procurement process […]
First published on 12 Jun 2019
Abstract Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies […]
First published on 03 May 2019
Dear Colleague, We would like to invite you to participate in a new clinical trial: “STATIC – STopping Aminosalicylate Therapy in Inactive Crohn’s Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial”. This is a fully funded study undertaken through a […]
First published on 23 Oct 2018
PROFILE is an investigator-led trial which aims to assess whether stratifying patients with Crohn’s disease from diagnosis based on a blood-test prognostic biomarker can help improve outcomes and quality of life. Aside from the biomarker it will also answer the […]